Tonix Pharmaceuticals Holding Corp. said Chief Executive Seth Lederman purchased 2,000 shares of common stock on August 27, 2026, through an IRA account at $13.79 per share, totaling $27,580. The transaction brings his indirect beneficial ownership to 11,005 shares via the IRA and one additional share through Lederman & Co., with the reporting person deemed a control person of these entities.
The stock was last quoted at $13.59, down from the purchase price, though InvestingPro data indicates a 9% gain over the past week. The company has a market capitalization of approximately $233 million and has been flagged by InvestingPro as appearing undervalued.
Tonix reported adjusted earnings per share of -$2.44 for the second quarter of 2026, beating the forecasted loss of -$2.71. Revenue reached $13.54 million, nearly doubling the expected $6.96 million. Net sales of its primary product, Tonmya, nearly tripled quarter-over-quarter to $11 million in its second full quarter on the market.
Analysts at Raymond James raised the price target for Tonix Pharmaceuticals from $26.00 to $27.00 while maintaining a Strong Buy rating. The firm noted that product sales had exceeded expectations. However, the company’s cash runway is projected to extend only into early 2027, which may constrain future operations.
